oral covalent KRAS(G12C) mutant-selective inhibitor Ph. I for solid tumors as monotherapy/combination with pembrolizumab Structure-informed optimization from Amgen’s sotorasib ACS Spring 2024 meeting presentation Merck/Taiho/Astex